– Baricitinib met the primary endpoint of hair regrowth across both dosing regimens – There are currently no FDA-approved treatments for AA INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of...
treatment News
Chiba, Japan – Pulmonary aspergillosis—a group of infectious respiratory diseases caused by various species of the fungus Aspergillus fumigatus—has a significant mortality rate across the globe. Currently, the first-line antifungal therapy in patients with chronic pulmonary aspergillosis and invasive pulmonary aspergillosis is azoles, which belong to a class of antifungal...
COPENHAGEN, Denmark – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for CHIKV VLP, the Company’s investigational chikungunya vaccine. The accelerated assessment, which is...
WAYNE, N.J. and EMERYVILLE, Calif. — Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar(R) (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or...
Berlin – Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments. “Nexavar has proven efficacy...
Berlin — Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer’s disease compared to healthy volunteers. BAY 94-9172 binds to the beta amyloid protein in the brain,...
BERLIN, Germany — Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior...
Houston, TX – Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors. A team led by researchers at...
Braunschweig, Germany – A new research paper was published in Oncotarget’s Volume 14 on December 1, 2023, entitled, “Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.” In multiple myeloma patients, high levels of soluble B-cell maturation antigen (sBCMA) can limit...
Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BASEL, Switzerland & CAMBRIDGE, Mass. – BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for BRUKINSA® (zanubrutinib) in Great Britain, for the treatment of eligible...